Abstract: A method has been found for the removal of microbial biofilm on surfaces in contact with systems, including but not limited to aqueous systems, which comprises adding to the aqueous system an effective amount of a polyalkyleneoxide polysiloxane surfactant to substantially remove microbial biofilm, from surfaces in aquatic systems, while presenting minimal danger to non-target aquatic organisms at discharge due to their very low discharge concentrations.

Abstract: A method of treating an airway in a mammalian body having a mouth, soft palate, uvula, throat and tongue. An implant-forming material is introduced into at least one of the soft palate and uvula for treating at least one of snoring and sleep apnea. An apparatus and kit are provided.

Abstract: Ion binding compounds and compositions may include compounds, polymers and compositions that include amine moieties. Ion binding polymers may be crosslinked amine polymers and may be used to remove ions, such as phosphate ions, from the gastrointestinal tract of animals, such as humans. Such compounds, polymers and compositions may be used therapeutically to treat a variety of medical conditions, such as hyperphosphatemia.

Abstract: A highly antimicrobial composition having characteristics of a lactic acid polymer such as biodegradability is prepared by combining a lactic acid oligomer with a metal salt thereof.

Abstract: Calcitonin drug-oligomer conjugates that include a calcitonin drug coupled to an oligomer including a single polyalkylene glycol moiety consisting of between 4 and 10 polyalkylene glycol subunits are disclosed. Pharmaceutical compositions including such conjugates and methods of treating bone disorders by administering such conjugates are also disclosed.

Abstract: A method for extending the gelation time of an oxidized polysaccharide to react with a water-dispersible, multi-arm amine to form a hydrogel is disclosed. The extension of the gelation time is accomplished by using a chemical additive. The method also extends the time for the hydrogel to become tack-free, and may also be used to decrease the degradation time of the hydrogel. The chemical additive reacts with the functional groups of the oxidized polysaccharide or the water-dispersible, multi-arm amine, thereby reducing the number of groups available for crosslinking. The use of the resulting hydrogel for medical and veterinary applications is described.

Abstract: Use of special non-foaming alkoxylated alcohols alone or their mixture with polysiloxanes as tank mixture additive for crop protection composition formulations.

Abstract: Aqueous formulations of soil release polyesters are claimed, which comprise from 50 to 90% by weight of soil release polyester and from 0.1 to 40% by weight of a phosphonic acid or of a phosphonate. The addition of the phosphonic acid or of the phosphonate allows the preparation of formulations of the soil release polyesters which are stable and have a low viscosity.

Abstract: The present invention provides a composition comprising a polymer of a ?-hydroxy short-medium chain fatty acid, which is used for delivering the ?-hydroxy short-medium chain fatty acid or an oligomer thereof to the large intestine. In case the composition is administrated orally, the composition will be delivered to the large intestine, without being degraded in the stomach or short intestine, and degraded by the large intestinal bacterial flora and release the short-medium chain fatty acid or an oligomer thereof. The released short-medium chain fatty acid or an oligomer thereof has useful physiological activities and is effective for treating or preventing inflammatory diseases or cancer in the large intestine.

Abstract: Bioabsorbable macromer compositions are provided including a polymeric component possessing a hydroxamate segment and a polymer segment. The polymeric component can be used by itself, or in some embodiments, combined with a second component, to form a macromer composition of the present disclosure. The resulting bioabsorbable macromer composition can be employed as an adhesive or sealant for medical/surgical uses.

Abstract: The present invention relates to a composition used as a vehicle for percutaneous absorption of Pharmaceutical and Cosmaceutical active agents that comprises Dimethiconol (hydroxyl-terminated polydimethydimethylsiloxane), dimethicone-350 (polydimethylsiloxane-350), cyclomethicone-5 nf (decamethylcyclopentasiloxane), alkymeth siloxane copolyol-lauryl peg/ppg 18/18 methicone (alkymethyl siloxane copolyol), cyclopentasiloxane and dimethicone Crosspolymer (silicone elastomer and decamethylcyclopentasiloxane), stearoxytrimethylsilane and stearyl alcohol (silicone wax), and deionized water.

Abstract: An aromatic polyanhydride comprising a repeating unit having the structure is disclosed, wherein Ar and R are selected so that the aromatic polyanhydride hydrolyzes to form a therapeutic salicylate, another non-steroidal anti-inflammatory, an antifibrotic aminobenzoate, or a vasoconstricting phenylethanolamine. Implantable medical devices, such as scaffolding implants for tissue reconstruction, drug delivery systems prepared from the aromatic polyanhydrides, as well as therapeutic dosage forms and treatment methods are also disclosed.

Abstract: The invention relates to the use of a silicone oil emulsion comprising 0.01-85 wt. % of silicones, particularly polydimethylsiloxanes, 0.01-90 wt. % of hydrophobic emulsifier that has an HLB value ranging from 1 to 7 and/or a hydrophilic emulsifier that has an HLB value ranging from 7 to 14 and/or 0.01-90 wt. % of a mixture of one or more hydrophobic and hydrophilic emulsifiers having an HLB value ranging from 1 to 14, and 0.1-99 wt. % of biocompatible saline solution, for producing a medicament as such or in combination with other medicaments or carrier materials for treating septic infections triggered by bacterial, viral, parasitic, and fungal causative agents or diseases in animals and humans caused by traumas.

Abstract: This invention relates to an improved monolithic drug delivery dosage form which releases a pharmaceutically active agent at a predetermined rate. The dosage form comprises a salted-out or crosslinked polymer and a pharmaceutically active agent. The salted-out or crosslinked polymer functions to polymerically entangle the pharmaceutically active agent but, progressively relax on contact with an aqueous medium in use to release the pharmaceutically active agent at a predetermined rate.

Abstract: A biodegradable polyurethane scaffold that includes a HDI trimer polyisocyanate and at least one polyol; wherein the density of said scaffold is from about 50 to about 250 kg m?3 and the porosity of the scaffold is greater than about 70 (vol %) and at least 50% of the pores are interconnected with another pore. The scaffolds of the present invention are injectable as polyurethane foams, and are useful in the field of tissue engineering.

Abstract: Polyanhydrides which link low molecular weight drugs containing a carboxylic acid group and an amine, thiol, alcohol or phenol group within their structure into polymeric drug delivery systems are provided. Also provided are methods of producing polymeric drug delivery systems via these polyanhydride linkers as well as methods of administering low molecular weight drugs to a host via the polymeric drug delivery systems.

Abstract: Carrier nanoparticles comprising a polymer containing a polyol coupled to a polymer containing a boronic acid, configured to present the polymer containing a boronic acid to an environment external to the nanoparticle and related compositions, methods and systems.

Abstract: Compositions and methods for transporting biologically active proteins and polypeptides, particularly across the blood-brain barrier, are provided.

Abstract: The invention provides compositions comprising a polyamidoamine (PAA) polymer comprising a pendant disulphide, sulphydryl, or activated sulphydryl moiety, and methods for their manufacture. The invention extends to the use of such polyamidoamine polymers to form cross-linked compositions, and hydrogels comprising the same, and the use of such compositions in various biological and non-biological applications, such as the delivery of biomolecules to target sites, and for tracking fluid flows. The invention also provides carrier particles, which may be used to deliver biomolecules, and to methods of treatment. The invention also provides a fluid tracking system for monitoring fluid flow.

Abstract: The invention relates to novel methods and kits for treating or preventing disease through the administration of random copolymers comprising amino acids tyrosine (Y), phenylalanine (F), alanine (A), and lysine (K). The invention also relates to the treatment of autoimmune diseases, such as multiple sclerosis, and to the administration of random copolymers in treatment regimen comprising formulations that are administered at intervals greater than 24 hours, or to sustained release formulations which administer the copolymer over a period greater than 24 hours. The invention further relates to methods for conducting a pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the formulations or dosing regimens of random copolymer described herein.

Abstract: The present disclosure relates to processes for preparing microparticles comprising peptides and to microparticles prepared by such processes. Also disclosed are methods for delivering a bioactive peptide to a subject in need of treatment by the bioactive peptide.

Abstract: Described are a method of killing microorganisms in aqueous industrial systems or products for industrial applications based on water by adding from 0.001 to 5% by weight of a water-soluble or water-dispersible polymer containing from 30 to 100 mol % of styrenesulfonic acid, from 0 to 40 mol % of an N-vinyllactam and/or N-vinylamine, and from 0 to 30 mol % of further free-radically polymerizable monomers as biocidal additive, and a method of protecting articles by applying an antimicrobial aqueous composition comprising such an additive.

Abstract: The present invention relates to a series of novel polyesters that are prepared by crosslinking polyglycerol and dimer acid. The nature of the water loving polyglycerol group as well as the fact that a C-36 fatty diacid is used in preparation of the products results in unique products.

Abstract: This invention relates to an oramucosal pharmaceutical dosage form in the form of a wafer. The wafer comprises a porous, hydroscopic, muco-adhesive polymeric matrix with at least one desired pharmaceutically active compound added thereto. The polymer is selected from a number of polymers having different dissolution rates and, in use when taken orally, the matrix adheres to an oramucosal surface to dissolve over a predetermined period of time to release the pharmaceutically active compound. The invention also extends to a method of manufacturing an oramucosal pharmaceutical dosage form in the form of a wafer which involves freeze drying or lyophilisation.

Abstract: A bactericidal or antimicrobial polymeric composition includes a hydrophilic first comonomer copolymerized to a second comonomer to produce a polymeric composition that is more hydrophilic or more bactericidal or antimicrobial in an aqueous solution than either of the comonomers alone. Methods for identifying bactericidal or antimicrobial polymers, methods for rendering materials bactericidal or antimicrobial, and methods for using bactericidal or antimicrobial compositions to kill or reduce bacterial or microbial growth are also described. Applications for the inventive compositions include their use in catheters, stents, medical devices, contact lenses; root canal fillers; fibers; paper; and/or wound dressing.

Abstract: The present invention provides a liquid polymer composition which can be implanted into a living mammal and which forms a solid hydrogel by in situ polymerization upon contact with body fluid and tissue. The composition also can be used as a coating on a medical device, or for the formation of a medical device. Formation of a solid implant or coating involves crosslinking of the adhesive with itself and with surrounding tissue. The liquid implant, by itself or in conjunction with various prostheses, can be used for many purposed, including fixation of the urethra for providing treatment for incontinence, and repair of herniations in the abdominal cavity, including rectocele, cystocele, enterocele, and inguinal hernia. The adhesive may be used to establish adhesion prevention during such repairs, in part by coating or being the material of a repair mesh.

Abstract: The present invention generally encompasses a medical article, such as a medical device or coating comprising an agent or combination of agents, wherein the agent is distributed throughout a polymeric matrix. The polymeric matrix comprises an agent and a poly(ester amide) having a design that was preselected to provide a predetermined release rate of the combination of agents from the medical article.

Abstract: Calcitonin drug-oligomer conjugates that include a calcitonin drug coupled to an oligomer including a single polyalkylene glycol moiety consisting of between 4 and 10 polyalkylene glycol subunits are disclosed. Pharmaceutical compositions including such conjugates and methods of treating bone disorders by administering such conjugates are also disclosed.

Abstract: Methods for analyzing, selecting, characterizing or classifying compositions of a co-polymer, e.g., glatiramer acetate are described. The methods entail analysis of pyro-glutamate in the composition, and, in some methods, comparing the amount of pyro-glutamate present in a composition to a reference standard. In some cases, the methods entail treating the co-polymer with pyro-glutamate aminopeptidase to cleave N-terminal pyro-glutamate residues.

Abstract: A method of delivering a therapeutic agent by providing a cross-linked polymer encapsulating the therapeutic agent to a site in a patient. The degradation rate of the cross-linked polymer is correlated with a local concentration of an indicator, and the therapeutic agent is released as the cross-linked polymer degrades.

Abstract: A composition for in situ formation and/or expansion of a polymer-based hemostatic agent to control bleeding includes a suitable amount of a polymer or polymer-forming component, hydrogen peroxide or chemical(s) capable of forming hydrogen peroxide, or a combination of both, and a decomposing agent for hydrogen peroxide. The decomposing agent includes an endogenously or exogenously supplied catalyst (other than catalase), or both, and/or the polymer or polymer-forming component.

Abstract: The present invention relates to polymer-modified quinone-containing and carbonyl-containing therapeutic agents, including polymer-modified ?-lapachone compounds, and methods of treating cancer by administering the polymer-modified therapeutic agents to a subject. Polymer-modification of therapeutic agents, such as ?-lapachone compounds, provides effective transport of polymer-modified therapeutic agents to tumor cells or tumor tissues by exploiting the EPR effect in tumor tissues.

Abstract: The invention relates to new compounds of Formula 1: [(O3/2)Si CH2CH2SX]a [Si(O4/2)]b[Si(O3/2V)]C wherein X is selected from CH2A,[CH2CH2NR1]pR2, CHCOX1CH2COX2,(CH2)eCO Y[(CH2)eSCH2CH2Si(O3/2)]m[CO2(CH2)eSH]n wherein A is the residue of an amino acid or derivative or salt of an amino acid of formula CHNR1R2COX3; R1 and R2 are independently selected from hydrogen, C1-20alkyl, and C1-20alkylaryl C1-12acyl R is selected from hydrogen, metal ion, C1-5alkyl, P is 1 to 100 and e is 1 or 2; X1 and X2 are independently selected from OR and NR1R2; X3 is selected from OR, NR1R2 or known amino acids and proteins or derivatives thereof; and Y is the residue of polyol having z or fewer hydroxyl groups substituted and m+n+1 is less than or equal to z; the free valences of the silicate oxygen atoms are saturated by one or more of silicon atoms of other groups of Formula 1, hydrogen, a linear or branched C1-12-alkyl group or by end groups R33M1O1/2 or by cross-linking bridge members or by polymer chains R3qM1(OR4)gOk/2 or AI

Abstract: The invention relates to a new cosmetic cleansing composition with improved skin conditioning and stability properties. Said cleansing composition contains (in % by weight) 5-60% of a surface-active agent, 0.1-10% of a diblock or triblock copolymer or a mixture thereof, 0.1-10% of a saturated liquid oligomer of an unsaturated fatty acid, said oligomer having more than 30 carbon atoms, 0.1-30% of an oil or fat, 10-80% of water, nd has an improved average foam stability ranging between 35 and 60 mm according to the foam stability test.

Abstract: A sanitising formulation comprising a solution of an acidic polymer and an anionic surfactant in a liquid vehicle. Suitable acidic polymers are those which include adjacent —[—CR1.COOH—]— units where R1 is defined in their structure, for example polymers based on maleic acid moieties which typically include —[—CH.COOH—CH.COOH—]— units, such as known Gantrez™ polymers. A suitable anionic surfact is sodium lauryl sulphate.

Abstract: Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as vital infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be a surfactant and, optionally, a carrier. The formulation may be administered as a powder where the particles consist basically of the material altering surface tension. The carrier may be a solution, such as an alcohol, although an aqueous solution may be utilized, or a material mixed with the material altering surface tension to form particles.

Abstract: The invention provides methods for suppressing the degradation of wood, wood products, and wooden structures due to infestation by wood-boring organisms, by use of a polyurea composition. The invention also provides for wood, wood products, and wood structures that are resistant to degradation due to borer infestation by use of a polyurea composition.

Abstract: Appetite suppression and weight management achieved through pre-meal ingestion of temporary gastric bulking agents in the form of superabsorbent polymer hydrogels (SAPHs) selected from among a group consisting of crosslinked polycarboxylic acid moieties is described. The preferred compositions and manufacturing methods of ultrapure preparations of ingestible forms; as well as the preferred methods of use, dosage and administration; distribution and delivery of SAPH materials are also described.

Abstract: The invention provides a composition comprising a mixture of polypeptides, wherein each polypeptide (a) is a copolymer of the amino acids L-glutamic acid, L-alanine, L-tyrosine, and L-lysine, and (b) may be in the form of a pharmaceutically acceptable salt; and wherein in the mixture (i) the polypeptides have an average molecular weight in the range 13,500 to 18,500 daltons, (ii) 13% to 38% of the polypeptides have a diethylamide group instead of a carboxyl group present at one end thereof, and (iii) 68% of the polypeptides have a molecular weight between 7,000 and 41,000 daltons. In an embodiment, the average molecular weight is 16,000 daltons. The invention also provides a method of treating a human subject afflicted with a neurodegenerative disease comprising administering to the human subject a therapeutically effective amount of any of the disclosed compositions so as to thereby treat the human subject.

Abstract: A method for inhibiting adhesion of bacteria to a surface of a biomedical device is disclosed. The method involves at least (a) incorporating one or more non-functionalized polymers having one or more hydrophilic moieties into an ophthalmic device that is a polymerization product of a comonomer mixture comprising: (i) a major amount of a non-silicone-containing hydrophilic monomer; and (ii) an end-terminal functionalized surfactant; and (b) inserting the ophthalmic device in the eye of a patient, wherein the at least one non-functionalized polymer migrates to the surface of the device in a sustained release manner to inhibit adhesion of bacteria to a surface of the biomedical device. Biomedical devices are also disclosed.

Abstract: The invention relates to polyammonium/polysiloxane copolymers, methods for production and use thereof.

Abstract: The invention relates to a polymeric condensation product which can be obtained by reacting guanidine or its salt with an alkylene diamine and an oxyalkylene diamine. Said condensation product has biocidal, in particular fungicidal, activity and is usable as a plant protection product.

Abstract: An aromatic polyanhydride comprising a repeating unit having the structure is disclosed, wherein Ar and R are selected so that the aromatic polyanhydride hydrolyzes to form a therapeutic salicylate, another non-steroidal anti-inflammatory, an antifibrotic aminobenzoate, or a vasoconstricting phenylethanolamine. Implantable medical devices, such as scaffolding implants for tissue reconstruction, drug delivery systems prepared from the aromatic polyanhydrides, as well as therapeutic dosage forms and treatment methods are also disclosed.

Abstract: A composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent is provided. A method of making a composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent, said method comprising admixing a biocompatible and pliable material with a physiologically acceptable suspending agent, is also provided. A method of augmenting soft tissue to provide long-term reduction of a skin defect, said method comprising stimulating collagen beneath the skin defect is further provided.

Abstract: An antimicrobial composition.

Abstract: The present invention relates to a solid anhydrous cosmetic composition comprising at least one non-spherical silicone elastomer and at least one silicone elastomer powder coated with a silicone resin. The invention also relates to a makeup process comprising the application to keratin materials of the said composition, and also to its use for obtaining a uniform makeup result that shows good fastness of the color over time.

Abstract: The use of ?-CDs as nucleating agents for PLA to provide an increase in polymer crystallinity is described. The improvement in increased crystallinity is related to the percentage of ?-CDs used. For the analyzed films, crystallinity was approximately 1.47% in the absence of a nucleating agent, and approximately 17.85% in the presence of the maximum amount of nucleating agent tested (e.g., 30%). Thus, improvement in processability, producability, and heat resistance of PLA will depend on the amount of ?-CDs loaded. Additionally, loading PLA with ?-CDs carrying an antifungal volatile is an effective way to increase PLA crystallinity besides avoiding fungal development when used in active packaging. In this case, the antifungal volatiles, along with changes in headspace concentration because of changes in crystallinity, may prolong the fresh produce shelf life.

Abstract: The present invention concerns a method of administering at least one active pharmaceutical agent to a patient in need thereof, which method comprises the intranasal administration of a composition comprising a therapeutically effective amount of this agent, phospholipids, one or more C2-C4 alcohols and water, wherein the concentrations of the phospholipids and the one or more alcohols in the composition are in the ranges of 0.2 to 10% and 12 to 30% by weight, respectively, with the water content of said composition being not less than 30% by weight, the phospholipids forming vesicles in said composition. Further are disclosed pharmaceutical compositions and combinations suitable for intranasal delivery.

Abstract: The invention relates to an amphiphilic-BMP polymer complex which is physically and chemically stable and soluble in water, characterised in that: the amphiphilic polymers comprise a hydrophilic polysaccharide skeleton functionalised with hydrophobic substituents and hydrophilic groups the BMP is selected from the group of therapeutically active BMPs (Bone morphogenetic Proteins), the polymer/BMP mass ratio is lower than or equal to 700. The invention also relates to the process for preparing the amphiphilic-BMP polymer complex in an aqueous medium and in the absence of organic solvents likely to denature the protein. The invention also relates to therapeutic compositions of an amphiphilic-BMP polymer complex according to the invention.

Abstract: The present invention relates to a cosmetic composition and to a pharmaceutical composition that comprise several agents of topical use and optionally sunscreens. This composition comprises an aqueous medium containing at least one highly polar substance without, however, having the inconveniences noticed in similar compositions of the prior art. These compositions combine the benefits from water-soluble active with the properties of softness and texture that are typical of products that comprise oily-alcoholic, oily or oily-waxy base. Further, the present invention relates to a process for preparing said cosmetic composition and pharmaceutical composition.